Q32 Bio Inc.

Biogen Ma Inc.

Ellen Garber Stark

Justin Andrew Caravella

Frederick Robbins Taylor

Susan L Kalled

Shelia Marie Violette

Vernon Michael Holers

Michael Storek

Michael Steven Curtis

Kelly C Fahnoe

Cheng Ran Huang

Joseph Arndt

Thomas O Cameron

Karl John Mortley Hanf

Janine Lisa Ferrant-orgettas

Robert Blake Pepinsky

Ellen Duggan Cahir-mcfarland

Nadia Giselle D'lima

The invention relates to anti-VLA-4 antibodies and binding fragments thereof. The invention further includes polynucleotides encoding said antibodies and binding fragments thereof and methods of manufacturing said antibodies and binding fragments thereof. The invention further includes methods of treating patients suffering from multiple sclerosis and/or epilepsy by administration of said antibodies and binding fragments thereof. The invention further includes methods of reducing the susceptibility to scrambling of a recombinant anti-alpha 4 antibody or a binding fragment thereof.

Anti-VLA-4 antibodies having reduced effector function

Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions.

Methods of treating complement mediated diseases with fusion protein constructs comprising anti-C3d antibody and a complement modulator

Fusion protein constructs comprising anti-C3d antibody and CR1 polypeptide

Fusion protein constructs comprising anti-C3d antibody and factor H

Growing community of inventors

Cambridge, MA, United States of America

Ellen Garber Stark